Longevity News

Mount Sinai Medical Center Researcher Co-Authors Peer-Reviewed Study on Inhaled Formulations Designed to Strengthen the Lungs’ Natural Defenses

Source: Fitt Insider - Press Releases • Published: 27 Aug 2026, 12:00

Mount Sinai Medical Center Researcher Co-Authors Peer-Reviewed Study on Inhaled Formulations Designed to Strengthen the Lungs’ Natural Defenses

Inhaled-formulation research that examines methods to boost the lungs’ natural clearance is presented in this article; expect a clear primer on the study’s aims and scientific context.

Key Takeaways
  • Preclinical results on inhaled formulations intended to boost lung innate clearance mechanisms
  • Results were published in the peer-reviewed journal AAPS PharmSciTech
  • Mount Sinai Medical Center researcher is listed as a co-author on the paper
Read Original Source

Continue exploring

Related longevity signals

Fitt Insider - Press ReleasesVero Combines Stanford's Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive HealthProteomic aging tools from academia are being adapted into a combined clinical and consumer predictive-health product; expect a forward-looking primer on that development.Longevity TechnologyLongevity AI taps real-world data for disease risk preventionLongevity AI’s collaboration with clinicians tests whether updating familiar clinical risk tools using modern healthcare records could improve preventive care. Read this article to see how a pragmatic, data-driven refresh of everyday medical prediction models is being studied.Fitt Insider - Press ReleasesCymbiotika Partners with Hundred Health to Bring Personalized Health Intelligence to Its CommunityPersonalized health data integration: a consumer wellness brand teams with a health-intelligence provider to offer customers tailored plan recommendations and data-driven guidance.Longevity TechnologyUnited Therapeutics seeks FDA approval for inhaled treatment for idiopathic pulmonary fibrosisAn article previewing news about a pharmaceutical company's regulatory submission for an inhaled therapy for a chronic lung condition, inviting readers to learn more about the filing and clinical trial context.